Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Feng , Adilijiang·Maimaitiming , YANG Shuyi ,  Dilimulati·Aisimutula

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R.China;

Corresponding author：

Dilimulati·Aisimutula, Email: 2499156828@qq.com

Keywords：

triple negative breast cancer; vascular endothelial growth factor; meta-analysis

DOI：

10.7507/1007-9424.201701020

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate expression of vascular endothelial growth factor (VEGF) protein in triple negative breast cancer (TNBC) and analyze its correlation between positive expression of VEGF protein and clinicopathologic features of patient with TNBC. Methods The published literatures relevant VEGF protein expression in TNBC and its relation to clinicopathologic features of patient with TNBC in China were retrieved by means of CNKI, Wanfang, VIP, China Biomedical, Chaoxing Medalink, PubMed databases, and other search tools. The literatures were independently filtered, extracted, and assessed by two reviewers according to the inclusion criteria and exclusion criteria. The meta-analysis was conducted by using RevMan 5.3 software. Results A total of 11 literatures were included and involved 1 838 patients (750 patients in the TNBC group and 1 088 patients in the non-TNBC group). The results of meta-nalysis showed that the positive expression of VEGF protein in the TNBC group was significantly higher than that in the non-TNBC group 〔OR=2.64, 95%CI (2.14, 3.26), P<0.000 01〕 , which was significantly increased in the TNBC patients with positive lymph node or stage Ⅲ–Ⅳ as compared with the negative lymph node or stage Ⅰ–Ⅱ 〔OR=0.30, 95% CI (0.14, 0.46), P=0.000 2; OR=0.43, 95% CI (0.29, 0.62), P<0.000 01〕 . However, the positive expression of VEGF protein was no associated with the age of patients with TNBC or tumor size (P>0.05). Conclusions VEGF highly expresses in TNBC and it is expected to be a new therapeutic target. Positive expression of VEGF protein is related to positive lymph node and late TNM stage, and it might be associated with prognosis of patient with TNBC.

Citation： DENG Feng, Adilijiang·Maimaitiming, YANG Shuyi, Dilimulati·Aisimutula. Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(8): 992-999. doi: 10.7507/1007-9424.201701020 Copy

1.	陈万青, 郑荣寿, 曾红梅, 等. 2011 年中国恶性肿瘤发病和死亡分析. 中国肿瘤, 2015, 24(1): 1-10.
2.	Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30(15): 1879-1887.
3.	Bae YH, Ryu JH, Park HJ, et al. Mutant p53-Notch1 signaling axis is involved in curcumin-induced apoptosis of breast cancer cells. Korean J Physiol Pharmacol, 2013, 17(4): 291-297.
4.	Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118(22): 5463-5472.
5.	Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J, 2011, 17(4): 377-382.
6.	张美芳. NF-κB、COX-2 和 VEGF 在三阴性乳腺癌中的表达、相关性及临床意义. 苏州大学, 2014: 1-40.
7.	孙洁. VEGF 表达及微血管密度与三阴性乳腺癌及非三阴性乳腺癌临床病理特征的关系. 广西医科大学, 2010: 1-55.
8.	左丽, 徐迎春, 李纲, 等. VEGF 在三阴性乳腺癌中的表达及临床意义研究. 世界最新医学信息文摘, 2015, 15(66): 1-2.
9.	谢闵, 许增祥, 孙圣荣. 环氧化物酶-2、血管内皮生长因子、拓扑异构酶 Ⅱ 在三阴性乳腺癌中的表达及临床意义. 中华实验外科杂志, 2014, 31(8): 1799-1801.
10.	马涛, 陆肖玮, 丁云. 三阴性乳腺癌 COX-2, VEGF 表达相关性及临床意义研究. 中国肿瘤外科杂志, 2012, 4(3): 145-148.
11.	史晓宇, 贾倩, 刘婷, 等. 三阴性乳腺癌中 VEGF、Ki-67 的表达及临床意义. 实用肿瘤杂志, 2016, 31(1): 35-38.
12.	蒋洪棉, 朱世龙, 李辛辛, 等. 三阴性乳腺癌中的 VEGF 表达及临床意义. 广西医学, 2013, 35(6): 743-744.
13.	管小青, 郑向欣, 吴骥, 等. 三阴性乳腺癌组织中 MMP-3 和 VEGF 表达的相关性及临床分析. 中国普外基础与临床杂志, 2014, 21(5): 567-571.
14.	袁媛, 张耀龙. 三阴性乳腺癌组织中 VEGF 的表达及其意义. 西部医学, 2014, 26(5): 606-607.
15.	赵筱倩, 陆肖玮. 血管内皮生长因子在三阴性乳腺癌中表达的临床价值分析. 医学理论与实践, 2016, 29(16): 2157-2158.
16.	谭林深, 秦海明, 朴瑛, 等. 异黏蛋白和血管内皮生长因子蛋白在三阴性乳腺癌组织中的表达及其临床意义. 中华肿瘤杂志, 2015, 37(11): 827-832.
17.	Zhang Y, Xu S, Lin J, et al. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast Cancer Res Treat, 2012, 136(2): 379-388.
18.	Valdehita A, Carmena MJ, Bajo AM, et al. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol, 2012, 348(1): 241-246.
19.	Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006, 12(8): 895-904.
20.	Cook MT, Liang Y, Besch-Williford C, et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Med Press), 2016, 9: 9-19.
21.	Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther, 2012, 13(11): 1123-1140.
22.	Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 2009, 20(10): 1639-1646.
23.	Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 2015, 34(24): 3107-3119.
24.	李紫瑶, 王淑梅, 王平, 等. VEGF 表达及微血管密度、淋巴管密度与三阴性乳腺癌及非三阴性乳腺癌临床病理特征的关系. 北京: 首都医科大学超声科学系第一届超声医学学术大会, 2014: 144-145.

1. 陈万青, 郑荣寿, 曾红梅, 等. 2011 年中国恶性肿瘤发病和死亡分析. 中国肿瘤, 2015, 24(1): 1-10.
2. Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30(15): 1879-1887.
3. Bae YH, Ryu JH, Park HJ, et al. Mutant p53-Notch1 signaling axis is involved in curcumin-induced apoptosis of breast cancer cells. Korean J Physiol Pharmacol, 2013, 17(4): 291-297.
4. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118(22): 5463-5472.
5. Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J, 2011, 17(4): 377-382.
6. 张美芳. NF-κB、COX-2 和 VEGF 在三阴性乳腺癌中的表达、相关性及临床意义. 苏州大学, 2014: 1-40.
7. 孙洁. VEGF 表达及微血管密度与三阴性乳腺癌及非三阴性乳腺癌临床病理特征的关系. 广西医科大学, 2010: 1-55.
8. 左丽, 徐迎春, 李纲, 等. VEGF 在三阴性乳腺癌中的表达及临床意义研究. 世界最新医学信息文摘, 2015, 15(66): 1-2.
9. 谢闵, 许增祥, 孙圣荣. 环氧化物酶-2、血管内皮生长因子、拓扑异构酶 Ⅱ 在三阴性乳腺癌中的表达及临床意义. 中华实验外科杂志, 2014, 31(8): 1799-1801.
10. 马涛, 陆肖玮, 丁云. 三阴性乳腺癌 COX-2, VEGF 表达相关性及临床意义研究. 中国肿瘤外科杂志, 2012, 4(3): 145-148.
11. 史晓宇, 贾倩, 刘婷, 等. 三阴性乳腺癌中 VEGF、Ki-67 的表达及临床意义. 实用肿瘤杂志, 2016, 31(1): 35-38.
12. 蒋洪棉, 朱世龙, 李辛辛, 等. 三阴性乳腺癌中的 VEGF 表达及临床意义. 广西医学, 2013, 35(6): 743-744.
13. 管小青, 郑向欣, 吴骥, 等. 三阴性乳腺癌组织中 MMP-3 和 VEGF 表达的相关性及临床分析. 中国普外基础与临床杂志, 2014, 21(5): 567-571.
14. 袁媛, 张耀龙. 三阴性乳腺癌组织中 VEGF 的表达及其意义. 西部医学, 2014, 26(5): 606-607.
15. 赵筱倩, 陆肖玮. 血管内皮生长因子在三阴性乳腺癌中表达的临床价值分析. 医学理论与实践, 2016, 29(16): 2157-2158.
16. 谭林深, 秦海明, 朴瑛, 等. 异黏蛋白和血管内皮生长因子蛋白在三阴性乳腺癌组织中的表达及其临床意义. 中华肿瘤杂志, 2015, 37(11): 827-832.
17. Zhang Y, Xu S, Lin J, et al. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast Cancer Res Treat, 2012, 136(2): 379-388.
18. Valdehita A, Carmena MJ, Bajo AM, et al. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol, 2012, 348(1): 241-246.
19. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006, 12(8): 895-904.
20. Cook MT, Liang Y, Besch-Williford C, et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Med Press), 2016, 9: 9-19.
21. Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther, 2012, 13(11): 1123-1140.
22. Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 2009, 20(10): 1639-1646.
23. Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 2015, 34(24): 3107-3119.
24. 李紫瑶, 王淑梅, 王平, 等. VEGF 表达及微血管密度、淋巴管密度与三阴性乳腺癌及非三阴性乳腺癌临床病理特征的关系. 北京: 首都医科大学超声科学系第一届超声医学学术大会, 2014: 144-145.

Previous Article
Effectiveness and safety analyses of electronic choledochoscopy in treatment of intrahepatic bile duct stones

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content